Masayoshi Tadehara

Kitasato University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Background and Aim No prospective studies have verified the incidence of cholecystitis in patients using the covered self‐expandable metallic stent. In this study, we aimed to investigate the incidence of cholecystitis and its risk factors after low axial force covered self‐expandable metallic stent placement for malignant distal biliary obstruction. Methods This multicenter prospective study included patients diagnosed with unresectable distal biliary obstruction between November 2019 and October 2022 who underwent low axial force covered self‐expandable metallic stent placement. Results The technical success in the 93 analyzed patients was 100% and clinical success was 98.9%. The 70‐mm covered self‐expandable metallic stent was the most used in 53 patients (57.0%), followed by the 80‐mm type in 27 patients (29.0%), 60‐mm type in 12 patients (12.9%), and 50‐mm type in 1 patient (1.1%). Cholecystitis after covered self‐expandable metallic stent placement occurred in six patients (6.5%). The median time to onset was 46 days (range, 16–315 days), with 1 case in the early stage and five cases in the late stage. There was one mild case, one moderate case, and four severe cases. The presence of tumor involvement at the orifice of the cystic duct was identified as an independent risk factor (odds ratio, 17.0; 95% confidence interval, 1.5–195.1; p = 0.023). Conclusions The presence of tumor involvement at the orifice of the cystic duct was an independent risk factor for the development of cholecystitis after low axial covered self‐expandable metallic stent placement. Trial registration: University Hospital Medical Information Network (UMIN) ( http://www.umin.ac.jp , registration number: UMIN 000038209)

Year:

2025

Background/Aims: To validate endoscopic ultrasound-guided tissue acquisition (EUS-TA) used in conjunction with stereomicroscopic on-site evaluation (SOSE) as a preoperative diagnostic tool for resectable pancreatic cancer (R-PC) and borderline resectable PC (BR-PC).Methods: Seventy-eight consecutive patients who underwent EUS-TA for suspected R-PC or BR-PC were enrolled. The primary endpoint was the sensitivity of EUS-TA together with SOSE based on the stereomicroscopically visible white core (SVWC) cutoff value. One or two sites were punctured by using a 22-gauge biopsy needle for EUS-TA, based on the SOSE findings.Results: We collected 99 specimens from 56 and 22 patients with R-PC and BR-PC, respectively. Based on the SOSE results, we performed 57 procedures with one puncture. The SVWC cutoff values were met in 73.7% and 73.1% of all specimens and in those obtained during the first puncture, respectively. The final diagnoses were malignant and benign tumors in 76 and two patients, respectively. The overall sensitivity, specificity, and accuracy of EUS-TA for the 78 lesions were 90.8%, 100%, and 91.0%, respectively. The sensitivity for malignant diagnosis based on the SVWC cutoff value were 89.5% and 90.4% for the first puncture and all specimens, respectively.Conclusions: The sensitivity of EUS-TA in conjunction with SOSE for malignancy diagnosis in patients with suspected R-PC or BR-PC was 90.4%.

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

光広 木田

Professor

Kitasato University

JAPAN
View details

Kosuke Okuwaki

Kitasato University

JAPAN
View details